test

Michael P DiGiovanna MD, PhD

Associate Professor of Medicine (Medical Oncology) and of Pharmacology

Clinical Interests

Breast Cancer


Board Certifications

1997
Medical Oncology, Board Certified

Patient Care Locations

michael_digiovannafaculty-clinicsfalsetruetrue6truefalsefalse

Clinical Trials

ConditionsStudy Title
Cancer, Breast - Female, and Breast - MalePhase III Randomized, Placebo-Controlled Clinical Trial Evaluating the Use of Adjuvant Endocrine Therapy +/- One Year of Everolimus in patients with High-Risk, Hormone Receptor-Positive and HER2/neu Negative Breast Cancer (S1207)
Breast - Female and Breast - MaleA Randomized, Multicenter, Open-label Phase III Study to Evaluate the Efficacy and Safety of Trastuzumab Emtansine versus Trastuzumab as Adjuvant Therapy for Patients with HER2-Positive Primary Breast Cancer who have Residual Tumor Present Pathologically in the Breast or Axillary Lymph Nodes following Preoperative Therapy (NSABP B50/Katherine Study)
Breast - FemaleA phase 1, open-label, dose-escalation study to evaluate the safety and tolerability of SGN-LIV1A in patients with LIV-1-positive metastatic breast cancer
Breast - FemaleS1222: FULVESTRANT ALONE VERSUS FULVESTRANT AND EVEROLIMUS VERSUS FULVESTRANT, EVEROLIMUS AND ANASTROZOLE: A PHASE III RANDOMIZED PLACEBO-CONTROLLED TRIAL IN POSTMENOPAUSAL PATIENTS WITH HORMONE-RECEPTOR-POSITIVE STAGE IV BREAST CANCER
Breast - FemaleA neoadjuvant phase II trial of aromatase inhibitors in combination with everolimus in postmenopausal women with hormone receptor positive/HER2 negative breast cancers with low and intermediate risk (less than or equal to 25) Oncoptype Dx Recurrence Scores

More Clinical Trials...

Edit Profile